Bellicum Pharmaceuticals Rakes in $69 Million - Closes Public Offering

Bellicum announced on 4/20/18 the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, including 1,200,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a public offering price of $7.50 per share. The aggregate offering size was $69.0 million, before deducting the underwriting discounts and commissions and other offering expenses.

Bellicum announced the offering just days after the FDA lifted its clinical hold on Bellicum's lead product BPX- 501. The FDA placed put Bellicum's development program on hold after reports of three incidents of encephalopathy possibly linked to BPX-501.

BPX-501 is intended  to improve outcomes in patients who receive partial-match hematopoietic stem cell transplants to treat blood cancers and inherited blood disorders. The potential benefit of BPX-501 is multi-fold: the patient gets the benefit of having T cells to fight infection, support engraftment, and prevent disease relapse and, should GvHD (graft vs host disease) occur, the CaspaCIDe safety switch can be activated to kill the toxic T cells.